Although healthcare organizations across Canada have made significant progress in developing health technology assessment (HTA) systems, there has been growing concern that their capacity to better manage health technology, more broadly, is lacking. In December 2016, the Federal/Provincial/Territorial Conference of Deputy Ministers of Health tasked the Canadian Agency for Drugs and Technologies in Health (CADTH) to propose a pan-Canadian health technology management (HTM) strategy. HTM extends beyond HTA, and essentially involves the management of a health technology through its life cycle (research and development, HTA, adoption, use and disinvestment). According to the 2017--2018 Business Plan of CADTH, one priority initiative is the transition of CADTH to an HTM enterprise, which is "an organization that supports real-world decision-making at all levels, monitors drug and non-drug utilization over the technology lifecycle, and supports implementation at the policy and practice levels" ([@R13]).

HTM requires knowledge of how new health technologies enter organizations. A recent survey of 47 healthcare organizations across Canada revealed a variety of mechanisms, one of which was the MDSAP (Report to Health Canada, funded through a Contribution Agreement \#6804-15-2013/10810069; [@R82]). Other mechanisms include piloting (providing a technology for a fixed number of cases) and clinical trials under protocol; neither of these involves the SAP process.

The MDSAP is laid out in Part 2 of the Canadian *Medical Devices Regulations* under the *Food and Drugs Act* -- Custom-Made Devices and Medical Devices Imported or Sold for Special Access (defined as "access to a medical device for emergency use or if conventional therapies have failed, are unavailable or are unsuitable") ([@R32], [@R34]; [@R61]; [@R30]). While the program has existed for almost 20 years, how it has been perceived and used remain unclear.

The objective of this study was to determine the landscape of information related to the MDSAP in Canada using scoping review methodology, and gain insights into its role in HTM.

Methods
=======

The scoping study approach (initially developed in 2005 by Arksey and O\'Malley) was selected because it is ideally suited to situations where the field of evidence is anticipated to be small and when a wide range of research and non-research material needs to be consulted ([@R4]; [@R22]; [@R58]). It consists of an iterative design with up to six stages.

Stage 1 -- Identify the research question
-----------------------------------------

The study question was developed iteratively while simultaneously keeping in constant focus the underlying aims of the review ([@R60]). Because the overall aim was to understand broadly what scholarly work had been done to date, and what the sources, volume and types of information were, the research question was defined as, "What is known from the existing literature about Health Canada\'s Medical Devices Special Access Program (MDSAP)?"

Stage 2 -- Identify relevant studies
------------------------------------

The search for relevant material was not limited to peer-reviewed sources, as the research purpose was to capture the breadth and range of information available. A list of keywords was developed iteratively, and a search strategy developed with the assistance of an information specialist. For peer-reviewed references, 13 electronic bibliographic databases were searched. A number of approaches to searching the grey literature were attempted with Google Scholar providing the most fruitful results. Links within web pages were also explored.

Searches were conducted between April 2015 and December 2017 (see [Appendix 1](https://www.longwoods.com/articles/images/HPL_Vol13_No3-Maier-App1.pdf)).

Stage 3 -- Select studies
-------------------------

As recommended by [@R58], the broad research question was then "\[combined\] with a clearly articulated scope of inquiry in order to guide the search strategy and establish parameters around study selection and data extraction." Inclusion and exclusion criteria were developed *post hoc* and were applied to all material by two reviewers. Material was considered in-scope if it related directly to Health Canada\'s MDSAP, including custom-made devices accessed through the program. Conversely, material was considered out-of-scope if it did not meet the inclusion criteria. Topics that were explicitly identified as being out of scope included:

-   programs from other countries;

-   special access programs for drugs or biologics (e.g., blood products);

-   investigational trials access;

-   healthcare delivery programs;

-   off-label use (when a technology has received marketing approval for one indication but is used for another indication); or

-   reimbursement mechanisms.

Press releases, patents, book chapters and non-English material were also excluded.

Importantly, the quality of the material was not formally assessed and did not form a basis for exclusion.

Stage 4 -- Chart the data
-------------------------

A standardized form was developed to record extracted information (see [Appendix 2](https://www.longwoods.com/articles/images/HPL_Vol13_No3-Maier-App2.pdf)). Two reviewers independently pilot-tested the form prior to full use. It contained two sections: one for general data (type and purpose of document, location, date of publication, authorship and sponsorship or affiliation disclosure) and one for specific data about medical devices (device name, type, and manufacturer; dates and quantities used) where these were provided.

Stage 5 -- Collate, summarize and report the results
----------------------------------------------------

Two separate "maps" were produced ([@R22]). The first, a literature map, characterized the range and depth of literature. The second, a device map, compiled the MDSAP-authorized medical devices found in the literature and categorized them by medical specialty using the Preferred Name Code classification system used by Health Canada ([@R45])

In addition to these two mapping constructs, a thematic analysis using open coding based on first impressions of the data ([@R74]) and synthesis was conducted, which yielded a concept map ([@R7]; [@R29]; [@R84]).

Stage 6 -- Consult expert opinion
---------------------------------

A subject matter expert consultation exercise was conducted. In stable contexts such as the health management field, relevant stakeholders are often "visible" ([@R85]), and the aim in selecting stakeholders is to secure competencies rather than to assure representativeness of all possible interest groups ([@R91]). Accordingly, individuals with extensive background in regulatory affairs and Health Canada\'s MDSAP were required. A representative from the medical devices industry and a regulator were consulted.

The subject matter experts were presented with background information on study rationale, methods and preliminary findings, and were asked to consider the completeness of the literature search and to identify additional references ([@R58]). No respondent identified any additional resources.

Results
=======

Literature map
--------------

A total of 173 documents were retrieved (see [Appendix 3](https://www.longwoods.com/articles/images/HPL_Vol13_No3-Maier-App3.pdf)).

Medical device map
------------------

No single source of information comprehensively listed the names of all medical devices obtained through the MDSAP. Information published by Health Canada was limited to national aggregate numbers of device applications processed annually ([@R47], [@R48]).

Fifty-three devices were identified, although some devices had more than one associated manufacturer or vendor because of corporate mergers and acquisitions. Forty-one of these devices were in the cardiovascular category (see [Appendix 4](https://www.longwoods.com/articles/images/HPL_Vol13_No3-Maier-App4.pdf)).

Literature themes
-----------------

Most of the peer-viewed papers that were found focused on individual technologies, and not on the MDSAP, which was frequently referenced only as the means to obtain access to the unlicensed technology. However, basic themes still emerged, and were categorized into organizing themes and then into "global" themes. The resulting concept map contained the following three global themes described below (Figure [1](#FG1){ref-type="fig"}).
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### Theme \#1: The MDSAP as an arbiter in health technology selection, playing an "approval" role

#### 1.1 Approval is for patients and clinical indications

The MDSAP provides approval for the patient as an individual, not patients in aggregate or at the population level, and is described as having "a single patient focus" ([@R46]). "... all patients received approval to have surgery from Health Canada on the Special Access Program ..." ([@R67]). In addition, small batches of devices for multiple individuals may be approved on a case-by-case basis ([@R48]).

Many authors indicated that patient eligibility was dependent upon the clinical indication ([@R3]; [@R9]; [@R14]; [@R18]; [@R24]; [@R31]; [@R66]; Rodés-Cabau et al. 2010; [@R75]; [@R76], [@R77]; [@R89]). [@R66] explained that MDSAP "provides approval for the use of silicone gel implants for the following patients: mastectomy, augmentation after failed saline implants (usually with ripples and folds) and primary augmentation if a saline failure is strongly predicted. Health Canada has not approved the use of gel implants for general use." More recently, [@R24] reported that "These cases were not 'run-of-the-mill' AVRs \[aortic valve replacements\]. Health Canada would not have authorized us to use a valve in that setting."

#### 1.2 Approval is for techniques and procedures

Regarding percutaneous aortic valve implantation, [@R89] wrote, "The procedure was approved by the Therapeutic Products Directorate, Department of Health and Welfare, Ottawa, Canada, for compassionate clinical use ..."

Further examples include needle ablation ([@R75]), left atrial appendage closure ([@R71]; [@R76]) and left atrial decompression ([@R3]). Some authors attributed approval of not only a procedure but also an entire program to the MDSAP. "In 2005, the Canadian TAVI \[transcatheter aortic valve implantation\] program was approved by the Department of Health and Welfare (Ottawa, Ontario, Canada) for compassionate clinical use ..." (Rodés-Cabau et al. 2010).

#### 1.3 Approval is for devices

The MDSAP approves the use of unlicensed alternatives to licensed medical devices when they are perceived to be clinically superior ([@R2]; [@R1]; [@R8]; [@R14]; [@R52]; [@R63]; [@R70]; [@R71]; [@R72]; [@R77]). [@R66] review of breast implants noted the availability of two types of implants: saline-filled (comprising 95% of implants), which were licensed, and gel-filled (5%), which, at the time, were unlicensed. Gel-filled implants were being used for "patients with exceptional circumstances, who received approval on compassionate grounds, because the quality of their final results would be more compromised with saline implants ... than with gel implants."

The uniqueness of the device (Is it sufficiently different from a licensed alternative?) was a consideration in approval. Minor variations in design and incremental improvements were considered insufficient for granting approval ([@R49]).

The MDSAP also approves custom-made devices ([@R34]; [@R49]). Two examples are custom-made endovascular stents ([@R59]; [@R62]; [@R63]) and a custom-made device for atrial septal defect closure ([@R31]).

#### 1.4 Approval depends upon moral judgments

"Compassionate use" was noticeably absent in government documents, but in primary studies, justification for MDSAP approval often related to compassion ([@R15]; [@R16]). [@R72] stated that the MDSAP was intended to offer treatment "in a patient population that had no other therapeutic option."

The requirement for patient consent is found in the "Undertaking" section of the application form. However, Health Canada has recognized that it has no jurisdictional authority in this area, because patient consent is established in the physician--patient relationship, and regulated at the provincial/territorial level through colleges of medicine ([@R40]). [@R80] wrote, "The prosthesis was approved for compassionate use by the department of Health and Welfare, Ottawa, Canada, in consenting patients declined for conventional reoperative surgery." Similarly, [@R42] wrote, "All patients were approved on a compassionate-use basis and gave written informed consent."

Institutional review was not a requirement for approval, but was mentioned as being sought in select cases ([@R9]; [@R19]; [@R25]). [@R6] noted, "In cases in which it was deemed that filter removal had to be postponed beyond 12 weeks for a medical indication, specific approval from both the ethics department and the Health Protection Branch was sought and granted." The requirement for approval from all three parties was noted by [@R21]. "Given the investigational status of the device used in this case report, approval was obtained from an institutional government-designated pediatric ethics committee and from the Canadian Special Access Programme of the Therapeutic Products Directorate, Health Canada. Parental written informed consent was obtained prior to the intervention."

#### 1.5 Approval depends upon evidence adequacy

Approval depends upon satisfying minimum evidence requirements as defined by Health Canada. Its Special Access Unit, with scientific reviewers and medical experts in the Bureau, decides on authorization based on the medical rationale provided and other information available ([@R49]). These evidence requirements are unique to the MDSAP because of their separate position (in Part 2) within the Medical Devices Regulations. A number of documents described this evidentiary uniqueness through comparisons with other programs.

[@R46] noted: "Separate regulatory provisions for drugs and devices have created inconsistencies between two programmes even though they have the same overarching intention, namely to provide emergency use access to products unavailable on the Canadian market." [@R88] concluded that many jurisdictions have "a lower evidentiary standard for devices compared to drugs."

Two articles compared the denial of a request for AIDS drugs with the approval of requests for breast implants and argued that there was less evidence of benefit to breast implant recipients (cosmetic) than there was to AIDS drug recipients (life-saving) ([@R17]; [@R39]).

Differences in evidence requirements for investigational testing, licensing and obtaining devices via special access were also raised. As indicated by Health Canada, "Medical devices authorized under Special Access do not undergo the same level of scrutiny required to obtain a medical device license or an authorization for investigational testing" ([@R49]).

Evidence thresholds were seen as being open to interpretation. A report of the Standing Committee on Health captured this sentiment with a committee member\'s question, "So I am wondering how you can determine that the risk is acceptable and therefore offer breast implants to all these women without having any long-term studies?" ([@R37]).

### Theme \#2: The MDSAP as a route of health technology procurement

#### 2.1 Pre-market access

The MDSAP provided an early route for professionals to access unlicensed products which subsequently were licensed, e.g., the Thermablate™ endometrial ablation technology ([@R87]) and the product Bio-Alcamid™ ([@R28]). Both were first used through MDSAP before receiving regulatory approval. More recently, Health Canada has stated that although the SAP plays a role by providing access to products that have not yet obtained market authorization ([@R46]), it is not intended as an "early market access" route for devices that are still in trials, still in development or awaiting licensure ([@R49]). However, the rapid increase in the number of requests to the MDSAP in recent years (see Section 2.3 below) may suggest its use as a mechanism for achieving early market access.

However, the MDSAP does appear to play a role in commercialization based on the sequential licensing of a device at an international level. The product may have been licensed in one jurisdiction and obtained via special access before receiving market approval in Canada or an additional jurisdiction. The Amplatzer Plug III (a CE-marked device) was accessed via MDSAP in Canada while under evaluation by the Food and Drug Administration in the US ([@R54]). A second example was the international roll-out of Thermablate, initially approved for sale by the State Drug Administration in China and also used to treat 54 women in Canada via the MDSAP before it received licensing. Approval for sale in Europe with CE marking followed ([@R93]).

A variation of the pre-market access concept was the case of silicone gel implants, whereby the products were initially licensed, then withdrawn from the market and obtained only by SAP and later marketed again after additional studies had demonstrated the products were safe ([@R11]; [@R43]; [@R81]).

#### 2.2 Non-market access

Certain devices obtained through the MDSAP have never been licensed in Canada. Accumulating the clinical evidence needed for market approval is sometimes seen as an insurmountable barrier. For heart valves, [@R90] explained, "It is unlikely that we will see rigorous testing of all potential combinations of available surgical and transcatheter valve types, frames configurations, and sizes." Interventions to treat rare diseases are also difficult to evaluate through clinical trials, because of the small number of patients ([@R88]). Custom-made devices are also challenging to evaluate for efficacy because each device is designed specifically for one individual ([@R56]; [@R59]).

Also, Canada represents a small potential market (e.g., the CE-labelled Innogenetics Inno-LIA HIV I/II Score, an unlicensed assay, can only be obtained through the SAP \[[@R55]\]).

#### 2.3 Logistics

The logistics of procurement were described in several papers, including Health Canada\'s recently issued Guidance document ([@R49]). Collectively, they provide information relevant to manufacturers, importers and healthcare professionals on topics such as: applicant qualifications, individual and batch requests, advertising, labelling, purchasing and sale, return of unused products, etc., within the context of the MDSAP.

The volume of SAP requests is also a logistics issue. In 2004, the Auditor General\'s report stated: "In 2002, Health Canada received 5,000 requests through the Special Access Program, a 683 percent increase in the last four years. Since the staff who process requests through the Special Access Program are the same as those who conduct pre-market evaluations, time spent dealing with these requests is time taken away from working on pre-market evaluations" ([@R35]). [@R49] similarly advised, "the Special Access Unit experiences a high volume of requests and follow-up communications," and the Therapeutic Products Directorate\'s annual performance reports drew attention to the application processing metrics of the MDSAP ([@R47]; [@R48]).

#### 2.4 Costs

The two relevant types of costs associated with the MDSAP are program costs and device costs. Devices being requested through MDSAP are exempt from application fees on the basis of the determination that "these devices have been exempted ... for public good reasons" ([@R33]). It is not clear how institutions pay for them, but Health Canada has offered guidance on two matters: (1) devices do not have to be provided free of charge by the manufacturer and (2) cost savings of the device are not an adequate justification for granting access ([@R49]). Only one study of cost-effectiveness of a device being acquired by SAP was found in the literature ([@R44]).

[@R88] discussed the cost of these devices to society from an ethical standpoint. "Potential cost burdens to society are difficult to predict as the funding implications of SAPs vary by location and program. Where health care payment systems are structured around evidence of safety, efficacy, and cost-effectiveness, SAPs have the potential to open the door to costly and unproven interventions, thereby subverting attempts to contain costs based on sound reasoning and evidence. Supplying unproven interventions entails opportunity costs; manufacturers may not develop alternative options and governments have less to spend on more effective interventions."

### Theme \#3: The MDSAP as a facilitator of health technology innovation

#### 3.1 Technology introduction

The MDSAP enables access to emerging technologies ([@R35]; [@R50]; [@R49]; [@R65]; [@R78]; [@R89]).

Several papers discussed technical feasibility, safety, procedural success rate, efficacy or short-term patient outcomes, all key information elements for technology uptake and diffusion (e.g., [@R19]; Helton et al. \[2011\] and Purdham et al. \[2012\] on cardiac valves; [@R23]; [@R77]). Health Canada has acknowledged the importance of publishing studies that report on such elements to communicate findings to the relevant clinical community ([@R49]).

The MDSAP has also been used to facilitate first-in-man-use applications of devices for patients "who would otherwise have no clinical options" and were given "careful scrutiny" ([@R49]). In 2005, during meetings of the Standing Committee on Health, the program was portrayed as providing access, with the healthcare professional described as the initiating force or the technology pioneer ([@R36], [@R37]).

#### 3.2 Technology evolution

The MDSAP provides access to evolving technologies (evolution of the device or of its use). In several papers, device evolution was phrased in the language of "generations," such as the third-generation HeartWare HVAD ([@R69]), second-generation endometrial ablation technologies ([@R87]) or second-generation transcatheter aortic valve ([@R8]) or in terms of improvement or evolution in time ([@R68]; [@R83]; [@R86]). Device evolution was expressed in terms of novel techniques or additional clinical indications. For example, [@R65] described how TAVI evolved from an antegrade transvenous transseptal approach to percutaneous retrograde transfemoral and anterograde transapical approaches. Occasionally, off-label use was reported as being intertwined with special access use: "The use of CSs \[covered stents\] in this study were obtained as an off-label application through a special-access government medical programmer \[sic\] ([@R57])." However, Health Canada distinguishes between the two and provides oversight of off-label use through the Investigational Testing provisions of Part 3 of the regulations ([@R49]).

#### 3.3 Technology routinely used

The MDSAP can influence the path of a technology to routine use. In some cases, after the first MDSAP approval, requests for the device have accelerated, as its adoption became more widespread. TAVI was one of the most documented technologies accessed through the MDSAP in Canada, its use rising exponentially as it became well-established for treating select patients ([@R26]; [@R53]). Silicone breast implants experienced a large increase in use in Ontario between 2000 and 2005 as plastic surgeons gained confidence in their safety ([@R79]).

Health Canada\'s position on the general use of devices obtained via SAP is that healthcare facilities should not expect to obtain individual devices on an ongoing basis, and that SAP approval does not suggest that the device is appropriate or suitable for general use ([@R49]). However, batch requests for devices routinely required in urgent, life-threatening circumstances are available on a case-by-case basis ([@R48]).

#### 3.4 Technology learning curve

Many non-drug health technologies are associated with learning curves, of which an important component is appropriate patient selection ([@R94]). This is reported as being particularly true with MDSAP devices ([@R19]; [@R72]; [@R80]; [@R92]). The MDSAP has advised that, where device training is required prior to use, the timing of training prior to submitting the SAP application should be considered ([@R49]).

Once devices are accessed, there is limited monitoring ([@R38]). To assist with the collection of outcomes data about specific new technologies, a number of registries have been created ([@R20]; [@R41]; [@R68]).

Some papers referred to the MDSAP in terminology associated with research, such as the "Canadian special access trial" and "Canadian special access study" ([@R27]; [@R44]). Other research-oriented articles noted that the device was initially obtained via special access, and then became licensed. "During the initial portion of this study, the PED was only available through a Health Canada compassionate-use program ([@R64])."

Limitations
===========

The limitations of this study include its reliance upon publicly available sources. There are two potential implications of this: (1) incompleteness of the medical devices identified and (2) over-representation of emerging technology and technology adoption themes, because of the nature of the research articles reviewed.

Discussion
==========

The three global themes of technology selection, procurement and innovation determined through the scoping review suggest that the MDSAP is one mechanism of HTM in Canada. In most cases, medical devices adopted by health systems have received regulatory approval from Health Canada. However, based on the findings of the review, many enter the same systems each year through the MDSAP. Because HTM takes a life cycle approach, the MDSAP, therefore, becomes an important consideration.

Diffusion of innovations starts from individual use cases, where authorizations are granted on ethical grounds after assessment of safety, effectiveness and risk/benefit for *individuals*. While the MDSAP is not intended to be an early market access route for medical devices, it involuntarily plays that role. As additional authorized requests for the emerging technology continue to build the evidence base, a critical mass is reached that permits (or disqualifies) device licensing and marketing. This decision is now no longer made on the basis of optimal care for an *individual*, but on the ethical grounds of safety and effectiveness at the *population* level.

Thus, the special access program does not appear to be used to circumvent licensing and sale for general (population) use. The MDSAP allows an emerging or evolving technology to demonstrate that it has promise and gather support and momentum. Where evidence is limited, the healthcare professional bridges the evidence gap by providing the medical rationale to Health Canada on the application form. This enables ethically desired patient outcomes as well as product commercialization.

The findings from this scoping review suggest that the MDSAP may be an effective commercialization strategy for industry. By providing education and training in the use of new technologies to physician pioneers, industry has a commercialization route available for cases in which clinical trial data are difficult to obtain. [@R10] investigated similar programs in the pharmaceutical context, known in Europe as "named patient programmes," and provided evidence that these programs were effective in increasing market share.

The review identified a number of evidence gaps and, in turn, areas for future research. They include investigating the magnitude and level of significance of the MDSAP in Canada. To what extent does it shape the healthcare landscape -- in which medical specialties or for which diseases? What is the health economic impact? It might be useful to take a different methodological approach (cf. a scoping review, such as this) to this, utilizing surveys and interviews of clinicians and industry representatives to get a deeper understanding of the SAP processes. Of note, in the area of custom-made devices, very little information is currently publicly available. Concept maps stratified by stakeholder groups should also be developed. The special access program is a unique federal route with a different mandate than the standard licensing route. Are the unique circumstances, opportunities and risks surrounding special access devices sufficiently understood at the provincial and territorial level? At the institutional level? And, as [@R12] implore, are they optimally managed?

Conclusion
==========

This paper provides the first scoping review and analysis of publicly available information pertaining to the Canadian Medical Devices Special Access Programme. Because this route appears to be a preferred one for the early introduction of innovative and rapidly evolving medical devices, it is important to understand it in the context of developing a pan-Canadian HTM approach. Such an approach would require the review of devices along their life cycles, and not just at the entry phase. The MDSAP may provide a means of early study of such devices, with subsequent studies being conducted as the device evolves (e.g., to second and third generations) or the understanding of its characteristics and functionalities become more evident. The MDSAP may provide the opportunity to generate evidence on early use, and permit the modification of policy regarding its continued utilization.
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